Effectiveness and Safety of Segmental Thoracic Spinal Anaesthesia using Isobaric Levobupivacaine 0.5 percent versus Hyperbaric Levobupivacaine 0.5 percent in Laproscopic Cholecystectomy - nil

开始日期2024-09-14

申办/合作机构

G.S.V.M. Medical College

CTRI/2023/03/050981 / Not yet recruitingN/A

TO STUDY THE ROLE OF SUPRACHOROIDAL INJECTION TRIAMCINOLONE IN NON-INFECTIOUS UVEITIS

开始日期2023-03-27

申办/合作机构

G.S.V.M. Medical College

100 项与 G.S.V.M. Medical College 相关的临床结果

登录后查看更多信息

0 项与 G.S.V.M. Medical College 相关的专利（医药）

登录后查看更多信息

1,731

项与 G.S.V.M. Medical College 相关的文献（医药）

2024-12-01·Indian Journal of Neurotrauma

How Dexamethasone Affects Necessity for Surgical Intervention for Chronic Subdural Hematoma: Systematic Review and Meta-Analysis

作者: Moscote-Salazar, Luis Rafael ; Gupta, Amit ; Das, Saikat ; Agrawal, Amit ; Krishnan, Prasad ; Atallah, Oday ; Maurya, Ved Prakash ; Rahman, Md Moshiur ; Mishra, Rakesh

AbstractThe effectiveness of dexamethasone in managing chronic subdural hematoma (cSDH) patients remains uncertain although the drug is widely used in this condition. The present systematic review aims to understand the role of dexamethasone in reducing the need for surgery in cSDH patients. This study was conducted as per the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched the electronic databases of PubMed, SCOPUS, Cochrane Central Register of Controlled Trials (the Cochrane Library), and ScienceDirect with a predefined search strategy. The population consisted of cSDH patients older than 18 years and treated primarily with dexamethasone. The primary outcome was the need for surgery after dexamethasone therapy in cSDH patients. The meta-analysis of a group of patients was done with the invariance method to estimate the pooled odds of the requirement for surgery after dexamethasone therapy. In the studies with a one-to-one comparison of dexamethasone with placebo/observation, the Mantel–Haenszel statistics were used to determine the odds of surgery. The quality of the studies was assessed with the Newcastle–Ottawa scale (NOS) and the Cochrane risk of bias tool was used to assess the risk of bias in randomized studies. In total, 598 studies were obtained from the database search and after applying the inclusion and exclusion criteria, 10 studies were finally selected for the qualitative and quantitative synthesis. One of the 10 studies was a randomized controlled trial (RCT), while the rest were observational studies. There were 653 patients who received the primary dexamethasone therapy. Of these, 388 patients did not require surgery, while 256 needed surgeries after the therapy. The pooled estimate of requirement for surgery after dexamethasone therapy was 0.41, with a 95% confidence interval of 0.37 to 0.45. A meta-analysis of the one-to-one comparison from three included studies showed a higher need of surgery in the (comparator) placebo/observation group than in the dexamethasone group with odds ratio of 7.16 (95% confidence interval: 2.21–23.13, with p = 0.0001). In addition, we identified the gaps in literature, and the complications and mortality reported in the studies. Dexamethasone is effective in reducing the requirement for surgery in some selected cSDH cases, although many patients still require surgical intervention.

2024-10-02·Journal of Asthma

Efficacy and safety of Once-Daily Vilanterol/Fluticasone furoate MDI in persistent asthma: Phase 3 OD-INHALE Study

Article

作者: Jain, Manish Kumar ; Mehta, Ravi T. ; Kumar, Raghumanda Sunil ; Mondal, Asish ; Barge, Vijaykumar Bhagwan ; Yadav, Harendra ; Redkar, Vivek Eknath ; Gupta, Neeraj ; Kumar, Avdhesh ; Pal, Amitava ; Rathore, Rahul Kumar ; Jaiswal, Ashok ; Daultani, Pavankumar

INTRODUCTIONOnce-daily inhalers have been shown to improve adherence leading to lesser discontinuation compared to twice- or thrice-daily inhalers in management of asthma. Combination of Vilanterol and Fluticasone Furoate (VI/FF) is approved for management of asthma and COPD and is available as a dry powder inhaler. Pressurized-Metered Dose Inhalers (pMDIs) offer ease-of-use and therapy alternatives for patients with low inspiratory flow. This study assessed the efficacy and safety of a new once-daily pMDI containing VI/FF in individuals diagnosed with persistent asthma.METHODSThis phase 3, double-blind, randomized controlled study assessed the non-inferiority of VI/FF (12.5 mcg/50 mcg & 12.5 mcg/100 mcg; 2 puffs once-daily) over Formoterol Fumarate and Fluticasone Propionate (FOR/FP, 6 mcg/125 mcg & 6 mcg/250 mcg; 2 puffs twice-daily) in patients with persistent asthma. Primary outcome was change from baseline in trough FEV1 at the end of study (12 weeks). Adverse events and number of exacerbations were used to evaluate safety.RESULTSA total of 330 patients were randomized into VI/FF (165) and FOR/FP (165). Trough FEV1 significantly improved in both the groups at week 12, with a mean difference (VI/FF minus FOR/FP) being 54.75 mL (95% CI, 8.42-101.08 mL, p = 0.02). The low dose VI/FF had similar efficacy to that of low dose FOR/FP and high dose VI/FF had similar efficacy to high dose FOR/FP. No serious adverse events were reported during the study.CONCLUSIONOnce daily VI/FF pMDI was non-inferior to twice daily FOR/FP pMDI in patients with persistent asthma.

2024-08-28·International Journal of Recent Innovations in Medicine and Clinical Research

Role of metabolomics in advancing precision medicine and personalized nutrition: A systematic review of clinical applications and future prospects

作者: Holkar, Shrirang Raoji ; Hivre, Manjusha Damodar ; Surkar, Prashant Vasantrao

Metabolomics, the comprehensive study of small molecules in biological systems, has emerged as a powerful tool in advancing precision medicine and personalized nutrition. This systematic review aims to evaluate the current clinical applications and future prospects of metabolomics in these fields. We searched PubMed, Scopus, and Web of Science databases for relevant studies published between 2010 and 2024. Out of 1,500 initially identified studies, 120 met our inclusion criteria. Our analysis revealed that metabolomics has significantly contributed to biomarker discovery, patient stratification, and treatment response prediction in various diseases, particularly in oncology and cardiology. In nutrition, metabolomics has enabled more accurate dietary intake assessment and personalized nutritional recommendations. Despite challenges in standardization and data interpretation, the integration of metabolomics with other omics technologies shows promise for revolutionizing healthcare and nutrition practices.

100 项与 G.S.V.M. Medical College 相关的药物交易

登录后查看更多信息

100 项与 G.S.V.M. Medical College 相关的转化医学

登录后查看更多信息